Reyhana Yahya1, Kirsten Berk2, Adrie Verhoeven1, Sven Bos1, Leonie van der Zee1, Jeanette Touw1, Gertraud Erhart3, Florian Kronenberg3, Reinier Timman4, Eric Sijbrands1, Jeanine Roeters van Lennep1, Monique Mulder5. 1. Department of Internal Medicine, division of Vascular Medicine and Pharmacology, Division of Medical Psychology and Psychotherapy, Erasmus MC, Erasmus University Medical Center, Rotterdam, Netherlands. 2. Department of Internal Medicine, division of Vascular Medicine and Pharmacology, Division of Medical Psychology and Psychotherapy, Erasmus MC, Erasmus University Medical Center, Rotterdam, Netherlands; Department of Dietetics and Division of Medical Psychology and Psychotherapy, Erasmus MC, Erasmus University Medical Center, Rotterdam, Netherlands. 3. Division of Genetic Epidemiology, Department of Medical Genetics, Molecular and Clinical Pharmacology, Medical University of Innsbruck, Innsbruck, Austria. 4. Department of Psychiatry, Division of Medical Psychology and Psychotherapy, Erasmus MC, Erasmus University Medical Center, Rotterdam, Netherlands. 5. Department of Internal Medicine, division of Vascular Medicine and Pharmacology, Division of Medical Psychology and Psychotherapy, Erasmus MC, Erasmus University Medical Center, Rotterdam, Netherlands. Electronic address: m.t.mulder@erasmusmc.nl.
Abstract
BACKGROUND AND AIMS: We aimed to evaluate the effect of statin treatment initiation on lipoprotein(a) [Lp(a)] levels in patients with dyslipidemia, and the interactions with the apolipoprotein(a) [apo(a)] phenotype, LPA single nucleotide polymorphisms (SNPs) and change in LDL cholesterol. METHODS: The study population consisted of patients with dyslipidemia, predominantly familial hypercholesterolemia, who first initiated statin treatment (initiation group; n = 39) or were already on stable statin treatment for at least 4 months (control group; n = 42). Plasma Lp(a) levels were determined with a particle-enhanced immunoturbidimetric assay before and at least 2 months after start of statin treatment in individuals of the initiation group, and at two time points with an interval of at least 2 months in the control group. High and low molecular weight (HMW and LMW, respectively) apo(a) phenotype was determined by immunoblotting, and the common LPA SNPs rs10455872, rs3798220 and rs41272110 by Taqman assay. RESULTS: Plasma Lp(a) levels did not increase significantly in the initiation group (median 20.5 (IQR 10.9-80.7) to 23.3 (10.8-71.8) mg/dL; p = 0.09) nor in the control group (30.9 (IQR 9.2-147.0) to 31.7 (IQR 10.9-164.0) mg/dL; p = 0.61). In patients with the LMW apo(a) phenotype, Lp(a) levels increased significantly from 66.4 (IQR 23.5-148.3) to 97.4 (IQR 24.9-160.4) mg/dL (p = 0.026) in the initiation group, but not in the control group and not in patients characterized by the HMW apo(a) phenotype. Interactions with common LPA SNPs and change in LDL cholesterol were not significant. CONCLUSIONS: Statins affect Lp(a) levels differently in patients with dyslipidemia depending on the apo(a) phenotype. Statins increase Lp(a) levels exclusively in patients with the LMW apo(a) phenotype.
BACKGROUND AND AIMS: We aimed to evaluate the effect of statin treatment initiation on lipoprotein(a) [Lp(a)] levels in patients with dyslipidemia, and the interactions with the apolipoprotein(a) [apo(a)] phenotype, LPA single nucleotide polymorphisms (SNPs) and change in LDL cholesterol. METHODS: The study population consisted of patients with dyslipidemia, predominantly familial hypercholesterolemia, who first initiated statin treatment (initiation group; n = 39) or were already on stable statin treatment for at least 4 months (control group; n = 42). Plasma Lp(a) levels were determined with a particle-enhanced immunoturbidimetric assay before and at least 2 months after start of statin treatment in individuals of the initiation group, and at two time points with an interval of at least 2 months in the control group. High and low molecular weight (HMW and LMW, respectively) apo(a) phenotype was determined by immunoblotting, and the common LPA SNPs rs10455872, rs3798220 and rs41272110 by Taqman assay. RESULTS: Plasma Lp(a) levels did not increase significantly in the initiation group (median 20.5 (IQR 10.9-80.7) to 23.3 (10.8-71.8) mg/dL; p = 0.09) nor in the control group (30.9 (IQR 9.2-147.0) to 31.7 (IQR 10.9-164.0) mg/dL; p = 0.61). In patients with the LMW apo(a) phenotype, Lp(a) levels increased significantly from 66.4 (IQR 23.5-148.3) to 97.4 (IQR 24.9-160.4) mg/dL (p = 0.026) in the initiation group, but not in the control group and not in patients characterized by the HMW apo(a) phenotype. Interactions with common LPA SNPs and change in LDL cholesterol were not significant. CONCLUSIONS: Statins affect Lp(a) levels differently in patients with dyslipidemia depending on the apo(a) phenotype. Statins increase Lp(a) levels exclusively in patients with the LMW apo(a) phenotype.
Authors: Michael J Koren; Monica Florio; Patrick Maurice Moriarty; Seth J Baum; Joel Neutel; Martha Hernandez-Illas; Howard S Weintraub; Helina Kassahun; Stacey Melquist; Tracy Varrieur; Saptarsi M Haldar; Winnie Sohn; Huei Wang; Mary Elliott-Davey; Brooke M Rock; Tao Pei; Oliver Homann; Jennifer Hellawell; Gerald F Watts Journal: Nat Med Date: 2022-01-13 Impact factor: 87.241
Authors: Weili Zheng; Michael Chilazi; Jihwan Park; Vasanth Sathiyakumar; Leslie J Donato; Jeffrey W Meeusen; Mariana Lazo; Eliseo Guallar; Krishnaji R Kulkarni; Allan S Jaffe; Raul D Santos; Peter P Toth; Steven R Jones; Seth S Martin Journal: J Am Heart Assoc Date: 2022-01-13 Impact factor: 6.106
Authors: Jonathan Golledge; Sophie Rowbotham; Ramesh Velu; Frank Quigley; Jason Jenkins; Michael Bourke; Bernie Bourke; Shivshankar Thanigaimani; Dick C Chan; Gerald F Watts Journal: J Am Heart Assoc Date: 2020-03-14 Impact factor: 5.501